Contact Us

Dr. Muzumdar graduated from Harvard College and received his Doctorate of Medicine from the Stanford University School of Medicine. He completed his internship and residency in Internal Medicine at Brigham and Women's Hospital and a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. He completed a postdoctoral research fellowship at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology before joining the Yale faculty. Learn more about Dr. Muzumdar>> His laboratory is interested in understanding the mechanisms by which genetic, environmental, and host factors contribute to cancer initiation, progression, and maintenance. Leveraging a combination of sophisticated genetically-engineered cell and animal models, the lab seeks to define the molecular basis for tumor cell and host adaptations that drive tumorigenesis. Furthermore, the lab uses genetic and pharmacologic approaches combined with novel nanoparticle-based delivery methods to augment or impede these adaptations and determine the consequences on cancer development in these models. The ultimate goal of this research is to identify novel approaches for cancer prevention and treatment.

Sherry received her undergraduate degree from the University of Connecticut in Physiology & Neurobiology and English. She then completed her Ph.D. at the University of Connecticut in Pharmaceutical Sciences. Her long-term research interests include understanding tumor evolution and identifying druggable vulnerabilities in pancreatic and lung cancers.

Xiangyu(Gigi) Ge graduated from Nanjing University, China in 2019 majoring in biosciences. She received the 2019 China Scholarship Council (CSC) Scholarship and was selected to join Yale Biological & Biomedical Sciences (BBS) Program. Out of great curiosity in cancer biology, she then decided to join Dr. Mandar Muzumdar's lab and will work on revealing the underlying mechanisms of required resistance to targeted therapies for KRAS in pancreatic cancer.

I am originally from Ossining, NY, a town in the suburbs of New York City. During high school, I began working in the cancer biology laboratory of Dr. Goutham Narla at Mount Sinai studying small molecules that activate a tumor suppressive phosphatase, PP2A. Being a part of this group galvanized my passion for cancer research and led me to study Molecular, Cellular, and Developmental Biology at Yale for undergrad. I completed my senior thesis in the laboratory of Dr. Craig Crews, studying PROteolysis TArgeting Chimeras (PROTACs) and stayed in the Crews lab for my two gap years before beginning medical school. For my PhD, I am interested in defining mechanisms of resistance to cancer targeted therapies and developing novel approaches to treat these refractory malignancies. Outside of the lab, I enjoy working out, visiting local breweries, and following Arsenal FC in the English Premier League.

Yanixa is a Genetics PhD candidate in the laboratory of Dr. Mandar Muzumdar. Her thesis work focuses on dissecting molecular and phenotypical differences of KRAS variants in cancer using a multi-omits approach. She obtained her Bachelors of Science degree in Biology with an emphasis in Genetics and Biomedicine from the University of Puerto Rico in Aguadilla. As a recipient of the NIH Ruth L. Kirschstein NRSA F31 pre-doctoral fellowship, Yanixa works at the Poorvu Center for Teaching and Learning as a Graduate Writing Lab (GWL) fellow, helping fellow graduate students navigate the fellowship application process. Her passion for providing equal access to health care and education, outreach and mentoring has driven her involvement with non-profit organizations such as HAVEN Free Clinic, New Haven Science Fair Program, and multiple student-based mentoring programs focused on increasing diversity and inclusion in STEM fields. She strongly believes that ensuring equal access to STEM opportunities for students from underrepresented backgrounds will allow them to reach their maximum potential, thrive in STEM, and successfully diversify the workforce.

I am interested in understanding the dynamics existing within the tumour microenvironment - and applying this knowledge to improve the clinical outcomes of immunotherapy. I am deeply passionate about exploring tumour-immune interactions.